LIFEOS GENOMICS CORPORATION

LifeOS Genomics Corporation specializes in thermal cycler nucleic acid amplification analysers for in vitro diagnostic (IVD) use in laboratory environments. These devices are primarily used for nucleic acid amplification, which supports applications like genetic testing and pathogen detection. The company’s focus is on laboratory-grade tools that enable precise molecular analysis.

LifeOS Genomics Corporation is headquartered in the United States. The company’s location influences its regulatory compliance framework, particularly for devices marketed in the U.S. market.

LifeOS Genomics Corporation’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry ensures traceability and transparency for Class II devices, which are subject to stricter controls due to their moderate risk profile. The UDI system helps track devices throughout their lifecycle, including post-market surveillance.

LifeOS Genomics Corporation’s devices fall under Class II regulatory classification. This classification is assigned based on factors like the device’s intended use (e.g., nucleic acid amplification for diagnostics) and associated risks. Class II devices require compliance with specific controls, such as performance standards or post-market surveillance, to ensure safety and effectiveness without requiring the rigorous premarket approval process of Class III devices.